Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRG-150 in Relapsed/Refractory Malignancies
NCT07730125Phase 2Not yet recruiting
- Sponsor
- CoRegen
- Start
- Nov 2026
- Primary completion
- Jun 2029
01
Overview
A Phase 2 trial of CRG-150 in breast cancer, triple-negative breast cancer (TNBC), prostate cancer (PCa), sponsored by CoRegen. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
CRG-150
03
Conditions
breast cancertriple-negative breast cancer (TNBC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07730125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730125.